Literature DB >> 10189890

Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth.

Y Oji1, H Ogawa, H Tamaki, Y Oka, A Tsuboi, E H Kim, T Soma, T Tatekawa, M Kawakami, M Asada, T Kishimoto, H Sugiyama.   

Abstract

To determine the role of the Wilms' tumor gene WT1 in tumorigenesis of solid tumors, expression of the WT1 gene was examined in 34 solid tumor cell lines (four gastric cancer cell lines, five colon cancer cell lines, 15 lung cancer cell lines, four breast cancer cell lines, one germ cell tumor cell line, two ovarian cancer cell lines, one uterine cancer cell line, one thyroid cancer cell line, and one hepatocellular carcinoma cell line) by means of quantitative reverse transcriptase-polymerase chain reaction. WT1 gene expression was detected in three of the four gastric cancer cell lines, all of the five colon cancer cell lines, 12 of the 15 lung cancer cell lines, two of the four breast cancer cell lines, the germ cell tumor cell line, the two ovarian cancer cell lines, the uterine cancer cell line, the thyroid cancer cell line, and the hepatocellular carcinoma cell line. Therefore, of the 34 solid tumor cell lines examined, 28 (82%) expressed WT1. Three cell lines expressing WT1 (gastric cancer cell line AZ-521, lung cancer cell line OS3, and ovarian cancer cell line TYK-nu) were further analyzed for mutations and/or deletions in the WT1 gene by means of single-strand conformation polymorphism analysis. However, no mutations or deletions were detected in the region of the WT1 gene ranging from the 3' end of exon 1 to exon 10 (the WT1 gene consists of 10 exons) in these three cell lines. Furthermore, when AZ-521, OS3, and TYK-nu cells were treated with WT1 antisense oligomers, the growth of these cells was significantly inhibited in association with a reduction in WT1 protein levels. Furthermore, constitute expression of the transfected WT1 gene in cancer cells inhibited the antisense effect of WT1 antisense oligomer on cell growth. These results indicated that the WT1 gene plays an essential role in the growth of solid tumors and performs an oncogenic rather than a tumor-suppressor gene function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10189890      PMCID: PMC5926055          DOI: 10.1111/j.1349-7006.1999.tb00733.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  52 in total

1.  Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis.

Authors:  P N Baird; P J Simmons
Journal:  Exp Hematol       Date:  1997-04       Impact factor: 3.084

2.  Preservation at subzero temperatures of mouse fibroblasts (strain L) and human epithelial cells (strain HeLa).

Authors:  W F SCHERER; A F HOOGASIAN
Journal:  Proc Soc Exp Biol Med       Date:  1954-11

3.  Breast tumor cell lines from pleural effusions.

Authors:  R Cailleau; R Young; M Olivé; W J Reeves
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

4.  Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions.

Authors:  L A Quinn; G E Moore; R T Morgan; L K Woods
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

5.  Classification of human colorectal adenocarcinoma cell lines.

Authors:  A Leibovitz; J C Stinson; W B McCombs; C E McCoy; K C Mazur; N D Mabry
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

6.  Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line.

Authors:  K Miyazaki; H Takaku; M Umeda; T Fujita; W D Huang; T Kimura; J Yamashita; T Horio
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

7.  [Establishment and characterization of a human scirrhus type gastric cancer cell line, GCIY, producing CA19-9].

Authors:  M Nozue; M Nishida; T Todoroki; Y Iwasaki
Journal:  Hum Cell       Date:  1991-03       Impact factor: 4.174

8.  Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.

Authors:  I A Drummond; S L Madden; P Rohwer-Nutter; G I Bell; V P Sukhatme; F J Rauscher
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

9.  Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.

Authors:  L W Engel; N A Young; T S Tralka; M E Lippman; S J O'Brien; M J Joyce
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

10.  Comparison of seven cell lines derived from human gastric carcinomas.

Authors:  T Motoyama; H Hojo; H Watanabe
Journal:  Acta Pathol Jpn       Date:  1986-01
View more
  53 in total

Review 1.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

Authors:  Lee M Krug; Tao Dao; Andrew B Brown; Peter Maslak; William Travis; Sara Bekele; Tatyana Korontsvit; Victoria Zakhaleva; Jedd Wolchok; Jianda Yuan; Hao Li; Leslie Tyson; David A Scheinberg
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

Review 3.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

4.  Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese population.

Authors:  Xiao-Wei Qi; Xiao-Dong Zheng; Bei-Ge Zong; Qing-Qiu Chen; Fan Zhang; Xin-Hua Yang; Yi Zhang; Jun-Lan Liu; Jun Jiang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 5.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity.

Authors:  Leonid Dubrovsky; Elliott Joseph Brea; Dmitry Pankov; Emily Casey; Tao Dao; Cheng Liu; David A Scheinberg
Journal:  Oncoimmunology       Date:  2016-08-03       Impact factor: 8.110

7.  The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.

Authors:  Hanfen Li; Yoshihiro Oka; Akihiro Tsuboi; Tamotsu Yamagami; Toru Miyazaki; Sei-ichi Yusa; Kotomi Kawasaki; Yukiko Kishimoto; Momotaro Asada; Hiroko Nakajima; Keisuke Kanato; Sumiyuki Nishida; Tomoki Masuda; Masaki Murakami; Naoki Hosen; Manabu Kawakami; Hiroyasu Ogawa; Fritz Melchers; Ichiro Kawase; Yusuke Oji; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

8.  Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.

Authors:  Aude G Chapuis; Gunnar B Ragnarsson; Hieu N Nguyen; Colette N Chaney; Jeffrey S Pufnock; Thomas M Schmitt; Natalie Duerkopp; Ilana M Roberts; Galina L Pogosov; William Y Ho; Sebastian Ochsenreither; Matthias Wölfl; Merav Bar; Jerald P Radich; Cassian Yee; Philip D Greenberg
Journal:  Sci Transl Med       Date:  2013-02-27       Impact factor: 17.956

9.  Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.

Authors:  Takuya Osada; Christopher Y Woo; Matthew McKinney; Xiao Yi Yang; Gangjun Lei; Heather G Labreche; Zachary C Hartman; Donna Niedzwiecki; Nelson Chao; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

Review 10.  Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.

Authors:  Mikio Kajihara; Kazuki Takakura; Tomoya Kanai; Zensho Ito; Yoshihiro Matsumoto; Shigetaka Shimodaira; Masato Okamoto; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.